Acute Sensorineural Hearing Loss – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Acute Sensorineural Hearing Loss – Drugs In Development, 2024 report and make more profitable business decisions.
Acute sensorineural hearing loss refers to a sudden and rapid reduction in hearing sensitivity, often exceeding 30 decibels, within a short period. Typically, this condition affects only one ear, accompanied by symptoms like dizziness and the presence of ringing in the ears, known as tinnitus (observed in 40% of cases). Various factors contribute to this condition, ranging from infections and inflammation to tumors, trauma, exposure to toxins, and disorders affecting the inner ear, such as Ménière’s disease.
The Acute Sensorineural Hearing Loss drugs in development market research report provide comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Sensorineural Hearing Loss and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Acute Sensorineural Hearing Loss | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 22 molecules, with 22 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Acute Sensorineural Hearing Loss therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Acute Sensorineural Hearing Loss pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acute Sensorineural Hearing Loss treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acousia Therapeutics GmbHAdare Pharma Solutions
Akouos Inc
AudioCure Pharma GmbH
Audion Therapeutics BV
Boehringer Ingelheim International GmbH
CILcare SAS
Hoba Therapeutics ApS
IMD Farm Co Ltd
Lineage Cell Therapeutics Inc
Mogrify Ltd
Myrtelle Inc
Nobelpharma Co Ltd
Oblato Inc
Otologic Pharmaceutics Inc
Otonomy Inc
Regeneron Pharmaceuticals Inc
Sensorion SA
Sinfonia Biotherapeutics Inc
Surrozen Inc
Zebra Biologics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Acute Sensorineural Hearing Loss reports